Amara/Amara-4

Amara/Amara-4 Warnings

glimepiride

Manufacturer:

Synmedic

Distributor:

Corbridge

Marketer:

Ambica
Full Prescribing Info
Warnings
Amara: In the initial weeks of treatment the risk of hypoglycemia may be increased and necessitates especially careful monitoring. Glucose levels in blood and urine must be checked regularly, as should additionally the proportion of glycated hemoglobin.
Alertness and reactions may be impaired due to hypo- or hyperglycemia. This may affect the ability to operate a vehicle or heavy machinery.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in